For patients with exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

Fuel them forward

PERTZYE® (pancrelipase) is formulated to contain pancreatic enzymes buffered with bicarbonate for nutrient absorption that gives your patients the opportunity to thrive.1-4

The PERTZYE® (pancrelipase) difference

PERTZYE microspheres are uniquely formulated to contain pancreatic enzymes with a bicarbonate buffer to simulate normal pancreatic digestive function in CF patients with EPI.1-4

The PERTZYE formulation also contains other inactive ingredients.


PERTZYE (pancrelipase) contains 3 different pancreatic enzymes (protease, lipase, and amylase) that are buffered with bicarbonate

The PERTZYE formulation also contains other inactive ingredients.



Capsules shown are not actual size and do not represent exact color.

Flexibility in dosing and delivery options

PERTZYE offers 4 different dosing strengths to help patients stay on PERTZYE from infancy to adulthood. Additionally, the 4,000 USP lipase units dosing strength is FDA approved for gastrostomy tube (G-tube) administration.1

PERTZYE (pancrelipase) offers 4 dosing strengths options

Capsules shown are not actual size and do not represent exact color.

Patients taking PERTZYE
experienced 78%
improvement in fat absorption
compared with placebo1,5
Explore efficacy data

Chiesi is committed to cystic fibrosis Learn about another Chiesi product

Help your cystic fibrosis patients start, stay, and save on their treatment

Supporting your patients is important to us. That’s why we are continuously improving the Chiesi CareDirect® support program. It’s customized with helpful resources designed just for patients with cystic fibrosis.

  • $0 copay
  • Free supply of PERTZYE§
  • One-on-one personalized support
A PERTZYE (pancrelipase) patient (young girl) is on the beach with her boogie board

*Restrictions apply. Limit one card per person per month. Patients receive $75 per month with every PERTZYE refill (annual savings: $900). Patients receiving Medicare, Medicaid, or that are participating in any other state or federally subsidized pharmacy benefit program are not eligible for certain components of this program. Please see full Terms and Conditions.

‡Restrictions apply. Limit one card per person per month. Patients receiving Medicare, Medicaid, or that are participating in any other state or federally subsidized pharmacy benefit program are not eligible for certain components of this program. Please see full Terms and Conditions.

§Free supply of PERTZYE is provided by Digestive Care, Inc. PERTZYE is shipped directly to patients and may also be available at doctor’s office.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.

Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

Most common adverse reactions (≥ 10%) are: diarrhea, dyspepsia, and cough.

Indication

PERTZYE® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Please click here for Full Prescribing Information and Medication Guide.



References: 1. PERTZYE (pancrelipase) Prescribing Information. Digestive Care, Inc., Bethlehem, PA: July 2017. 2. Borowitz DS, Grand RJ, Durie PR, Consensus Committee. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr. 1995;127(5):681-684. 3. Manual of Clinical Enzyme Measurements. Freehold, NJ: Worthington Biomedical Corporation; 1972:1-56. 4. Ishiguro H, Steward MC, Naruse S, et al. CFTR functions as a bicarbonate channel in pancreatic duct cells. J Gen Physiol. 2009;133(3):315-326. 5. Konstan MW, Accurso FJ, Nasr SZ, Ahrens RC, Graff GR. Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis. Clin Invest. 2013;3(8):723-729.